HighRes will integrate a multi-system robotics platform with advanced software control architecture for peptide and large molecule therapeutics research

medic-563423_640

HighRes and Novo Nordisk partnered to develop new robotics platform for drug discovery (Credit: Darko Stojanovic/Pixabay.)

Laboratory automation systems provider HighRes Biosolutions and Novo Nordisk have joined forces to design an advanced robotics platform for high-throughput biologics engineering and characterisation.

Under the collaboration, HighRes will integrate a multi-system robotics platform with advanced software control architecture, for digital transformation for peptide and large molecule therapeutics by Novo Nordisk.

Novo Nordisk is a Denmark-based healthcare company, focused on obesity, haemophilia, growth disorders and other serious chronic diseases. The firm operates in 80 countries and markets through its approximately 42,200 employs.

Novo Nordisk global research technologies senior vice president Lars Fogh Iversen said: “In order to maintain our leadership within biologics engineering we are investing in a fully automated and digital design platform.

“This investment is linked to our build-up in AI and advanced analytics and demonstrates Novo Nordisk’s commitment as a world-leading biologics research company.”

HighRes to develop robotics platform that integrates with advanced capabilities of Novo Nordisk

The new automated facility is said to feature various automated and integrated cells for production, characterisation and functional analysis of biologic compounds.

The scope of the robotics platform includes a full range of products, starting from small synthetic peptides to recombinantly expressed large proteins, along with chemical modification of molecules.

The company claimed that it intends to develop a system that completely integrates with a modern data infrastructure, data science and machine learning capabilities of Novo Nordisk.

HighRes is engaged in designing and making advanced laboratory automation systems, dynamic scheduling software and lab automation instruments.

The company claimed that it offers flexible and modular solutions to its clients, for scaling and reconfiguring their automation equipment.

HighRes Biosolutions CEO Ira Hoffman said: “We are very excited to be working with Novo Nordisk on their Lab of the Future. We believe that the combination of our capabilities, products and vision make us the ideal partner for their digital transformation.”